Dietary Supplements and Inflammation Phase-2

摘要： COBRE第2阶段膳食补充剂和炎症（CDSI）的总体目标 南卡罗来纳州（USC）将继续在第一阶段成功的基础上推进研究 基础设施，特别是在膳食补充剂和炎症领域，通过促进多学科 初级研究人员从事的研究，使他们在获得NIH R01资助方面具有高度竞争力， 类似的校外资金来进行他们的研究。总体目标是研究植物如何 可减轻炎症并用于预防和/或治疗炎性疾病。CDSI将测试 植物或其成分通过表观遗传调节来调节炎症的总体假设 免疫细胞的功能。在第一阶段，我们在成功过渡所有 把我们的初级教员变成了校外资助的调查员此外，我们成功地确保了NIH 补充和替代医学（CAM）中心（P01）炎症的表观遗传调节，在 哪些"毕业"教师领导这些项目，从而为CDSI的可持续发展铺平道路。因此，在本发明中， CDSI将补充CAM研究，并在南加州大学的炎症研究中创造一个独特的利基。的 COBRE第二阶段的主要目标是建立多学科研究，以确定表观遗传 植物调节炎症的机制，使它们或它们的类似物可用于 预防和/或治疗炎性疾病。美国人口每年在CAM上花费约339亿美元，其中 约200亿美元用于膳食补充剂。越来越清楚的是，炎症在 不仅是自身免疫性疾病的发病机制，而且还包括广泛的临床病症， 心血管疾病、神经退行性疾病、肥胖症、衰老和癌症。因此，理解 植物或其成分对炎症的作用方式，可能导致新的治疗方式， 广泛的临床意义。CDSI的目标将通过促进多学科 通过高度结构化的指导，由4名初级教员在炎症性疾病领域进行研究 由一名高级教员和一名最近毕业的COBRE Phase-1教员进行。初级教员 将有机会获得最先进的研究核心设施，包括流式细胞术，显微镜和成像 核心和生物分析核心，以帮助表观遗传学研究。该计划将由外部顾问进行评估 由国家认可的科学家组成。此外，通过机构支助， 南加州大学将招募和指导终身教职的初级教师，以支持和推进炎症研究。 CDSI的长期目标是建立一个自我维持的，国家和国际公认的 膳食补充剂和炎症研究的多学科中心，通过促进创新，教师 创业，合作研究项目，如PPGs和机构培训补助金，以及 临床/转化研究。

Abstract: The overall objective of the COBRE Phase-2 for Dietary Supplements and Inflammation (CDSI) at the University of South Carolina (USC) is to continue to build on the success of Phase-1 and advance the research infrastructure specifically in the area of dietary supplements and inflammation by promoting multi-disciplinary research pursued by junior investigators so that they become highly competitive in obtaining NIH R01 grants and similar type of extramural funding to pursue their research. The overall objective is to investigate how botanicals can attenuate inflammation and be used to prevent and/or treat inflammatory diseases. The CDSI will test the overarching hypothesis that botanicals or their constituents regulate inflammation through epigenetic regulation of immune cell functions. In Phase-1, we have made outstanding progress in the successful transition of all of our junior faculty into extramurally-funded investigators. Additionally, we were successful in securing NIH Complementary and Alternative Medicine (CAM) Center (P01) for Epigenetic Regulation of Inflammation, in which ‘graduated’ faculty are leading the projects, thereby paving the path towards sustainability of CDSI. Thus, the CDSI will complement the CAM Research and create a unique niche at USC in inflammation research. The main goal of COBRE Phase-2 is to establish multi-disciplinary research that will identify the epigenetic mechanisms through which botanicals modulate inflammation so that they or their analogs can be used to prevent and/or treat inflammatory diseases. The US population spends ~$33.9 billion/year on CAM, of which ~$20 billion is on dietary supplements. It is becoming increasingly clear that inflammation plays a critical role in the pathogenesis of not only autoimmune diseases but also a wide range of clinical disorders including cardiovascular diseases, neurodegenerative disorders, obesity, aging and cancer. Thus, understanding the mode of action of botanicals or their constituents on inflammation, could lead to novel treatment modalities with far ranging clinical implications. The CDSI goal will be accomplished through promotion of multi-disciplinary research pursued by 4 junior faculty in the area of inflammatory diseases, through highly structured mentoring of each by a senior faculty and a recently graduated faculty member of the COBRE Phase-1. The junior faculty will have access to state-of-the-art research core facilities that include Flow Cytometry, Microscopy and Imaging Core, and Bioanalytical Core, to aid epigenetic studies. The program will be evaluated by an External Advisory Committees consisting of nationally recognized scientists. Additionally, through institutional support, 5 new tenure-track junior faculty will be recruited and mentored at USC to bolster and advance inflammation research. The long term objective of the CDSI would be to build a self-sustaining, nationally and internationally recognized multi-disciplinary Center for dietary supplements and inflammation research, by promoting innovation, faculty entrepreneurship, collaborative research projects such as PPGs and Institutional training grants, and clinical/translational research.